Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript

Jun 23, 2020 / 06:30PM GMT
Release Date Price: R$49.06 (-2.15%)
Robert Adam Hopkins
BofA Merrill Lynch, Research Division - MD of Equity Research

Okay. Good afternoon, everybody, and welcome to the next presentation. I'm Bob Hopkins, here with Geoff Meacham who covers large-cap pharma and devices. And this next section, we're thrilled to have J&J here with us for a fireside chat. Joe Wolk, J&J's well-known Executive Vice President, Chief Financial Officer, is on with us; as well as Chris and Lisa and Matt from the Investor Relations team. And just a quick plug for that team. They are a phenomenal resource for investors, and I encourage everybody to take advantage of the great resource that J&J gives to all investors. So Joe, I just want to thank you for joining us this afternoon. It's a pleasure to be with you virtually.

Joseph J. Wolk
Johnson & Johnson - Executive VP & CFO

Bob, thanks for your time and your interest as well as that, that's extended by everybody on the phone. Certainly appreciate being invited by yourself and Geoff to talk a little bit about our company today.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot